Table 1 Patient demographics, pathology, and imaging
From: I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma
Patient no. | Age/sex | Race | Child-Pugh score | Etiology | TNM | AJCC path grading | I-124 Czb baseline 10 mg | I-124 Czb second injection (mg/kg) | I-124 Czb third injection 10 mg | Day between IHC sample and I-124 Czb second injection | IHC H membrane | IHC H cytoplasmic | SUVmax tumor of biopsied lesion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 63/M | White | A | None | IIIB | Poorly differentiated | Yes | 5 | ND | 41 | 4 | 7 | 7 |
2 | 71/M | White | A | None | IV | Cannot be assessed | Yes | ND | ND | 18 | 155 | 84 | 30.9 |
4 | 67/M | White | B | None | IV | Cannot be assessed | Yes | ND | ND | 34 | 145 | 15 | 7.3 |
5 | 69/F | Asian | A | None | IIIC | Well differentiated | Yes | 5 | ND | 46 | 30 | 25 | 5.8 |
6 | 64/M | White | A | None | IIIB | Cannot be assessed | Yes | ND | ND | 11 | 0 | 15 | NA |
7 | 82/M | White | A | None | IIIB | Moderately differentiated | Yes | 5 | Yes | 46 | 40 | 13 | 6.7 |
8 | 62/M | White | A | HepC | IV | Cannot be assessed | Yes | ND | ND | 21 | 4 | 6 | 6.8 |
9 | 81/M | Asian | A | HepB | N/A | Well differentiated | Yes | 2.5 | Yes | 38 | 5 | 85 | 8.1 |
10 | 58 M | Asian | A | HepB | I | Undifferentiated | Yes | ND | ND | 10 | 165 | 150 | 12.8 |
11 | 68/F | A/A | A | HepC | IV | Cannot be assessed | Yes | ND | ND | 14 | 1 | 25 | 4.9 |
13 | 58/M | A/A | A | HepC, Alcoholic | IIIA | Poorly differentiated | Yes | ND | ND | ND | ND | ND | ND |
14 | 60/M | White | A | HepC | IV | Cannot be assessed | Yes | 2.5 | Yes | 27 | 2 | 62 | 8.4 |
16 | 59/M | White | A | Alcoholic | IV | Moderately differentiated | Yes | 2.5 | ND | ND | ND | ND | ND |
17 | 50/M | White | A | HepB | IV | Well differentiated | Yes | 2.5 | ND | ND | ND | ND | ND |